echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: EGFR: A stable marker of bone metastasis in prostate cancer.

    Br J Cancer: EGFR: A stable marker of bone metastasis in prostate cancer.

    • Last Update: 2020-09-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Prostate cancer (PCa) is one of the most common malignancies among men worldwide.
    despite a 5-year survival rate of nearly 100% in patients with local PCa, metastatic prostate cancer remains incurable.
    , there is an urgent need for markers to detect the initial stage of monitoring tumor metastasis, the likelihood of tumor recurrence, and the preferred site for predicting metastasis in order to personalize treatment of patients.
    previous studies have shown that intersessional transformation (EMT) and plasticity are associated with the transfer of PCa.
    addition, EGFR (epidermosphel growth factor subject) has also been shown to play a vital role in the development of prostate cancer.
    there is now evidence that EGFR expression levels are associated with the re-emergence of prostate-specific antigens (PSA), the high risk of bone metastasis, and the malignancy of tumors.
    , however, the complex relationship between the expression of EGFR and the characteristics of PCa and PCa transfer needs further study.
    EGFR over-expression in primary tumors tracked the over-expression status of EGFR in metastasis (EGFRover) in metastasis samples of 1,039 primary tumors, 39 circulating tumor cells in high-risk patients with Damico, and 21 cases of de-resistance PCa.
    researchers detected that EGF was over-expressed in 14 percent of primary tumor samples, corresponding to a shorter, non-transferable lifetime, which is a separate indicator of poor overall survival.
    further studies of EGFR expression in cancer metastasis have found that EGFR over-expression status is associated with pre- and pre-metastasis esophageal and rich collagen fiber content of tumor cells.
    all circulating tumor cells (detected in 13% of cases) tested positive for EGFR, a result independent of their EMT esoploid.
    EGFRover was more common in desirable resistant osteosarcoma (29 percent of patients).
    study, the over-expression of EGFR is a stable, EMT-independent marker of prostate cancer's metastasis to the bone.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.